Lipoprotein (a) [Lp(a)] is a human plasma lipoprotein with unique structural and functional characteristics. Lp(a) is an assembly of two components; a central core with apolipoprotein B100
Introduction
evidence from Lp(a) lowering trials is still very limited. Hence, larger studies of longer duration of potent Lp(a) lowering therapeutics in high-risk individuals are warranted to substantiate these advices.
Below, we will discuss past and present therapeutics that have achieved varying levels of Lp(a) lowering (Table 1) and highlight the concomitant effects of these compounds on apoB and Lp(a) levels. (Figure 1 ).
Statins
Therapeutic options for Lp(a) arose alongside the developmental track for LDL-C lowering drugs (Table 1) . Statins have been around for more than 20 years and exert the majority of their LDLlowering capacity by up regulating LDL receptor expression, subsequently leading to increased LDL-C clearance. Due to the structural similarities between Lp(a) and LDL, a hitchhiking-like process was proposed whereby Lp(a) attached to LDL could be removed by the LDL-receptor (LDLR) pathway.
Although statins represent one of the best-studied compounds in clinical research, there is no final answer to its effect on Lp(a) levels. Most recent studies report that statins do not affect Lp(a) levels:
post-hoc analysis of 'Treating to New Targets' (TNT) (14) and 'Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin' (JUPITER) trial (15) ; or perhaps even increase Lp(a) levels in 'Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering' (MIRACLE) (16) , 'Reversal of Atherosclerosis with Aggressive Lipid Lowering' (REVERSAL) (17) and 'Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin' [ASTRONOMER] (18) . In contrast several smaller studies report decreases in Lp(a) levels (19) (20) . Overall there is no clear evidence that statin treatment lowers Lp(a) levels. Hence, the LDL receptor does not seem to be a major contributor to Lp(a) clearance in humans (21) . A detailed discussion of this topic will be presented elsewhere in this Thematic Review. The role of LDL receptor in Lp(a) clearance will be codiscussed again in the section on PCSK9 inhibition.
Niacin
Beyond the well-known capacity of niacin (nicotinic acid) to favorably influence the levels of high density lipoprotein cholesterol (HDL-C), LDL-C and triglycerides (TG), niacin also decreases plasma by guest, on September 8, 2017 www.jlr.org Downloaded from levels of Lp(a). Potential mechanisms by which niacin lowers Lp(a) comprise a reduced apo(a) transcription (22) , or a reduced apoB secretion via the inhibition of TG synthesis (23) . The inhibitory effect of niacin on Lp(a) production was recently substantiated in vivo in an apo(a) kinetic study investigating the effect of extended release niacin in 8 obese male subjects with hypertriglyceridemia.
Niacin resulted in a 50% reduction of newly synthesized apo(a), which was partly compensated by decreased catabolic clearance. The net effect was a 20% lowering of Lp(a) levels by niacin in this study. (24) In recent years, two large randomized controlled trials have studied the clinical effects of nicotinic acid derivates. In 'Atherothrombosis Intervention in Metabolic Sydrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes' (AIM-HIGH) the effect of extended release niacin on a background of statin treatment was tested in 3,414 patients with stable atherosclerotic disease, low baseline HDL-C and elevated TG levels and niacin treatment resulted in 21% Lp(a) reduction, compared to placebo. (25) The larger 'Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events' (HPS2-THRIVE) had a similar approach and enrolled 25,773 high risk patients with prior cardiovascular disease who were randomized to receive extended release niacin in combination with laropiprant or placebo, on top of statin with/without ezetimibe background therapy. (26) The prostaglandin D2 antagonist laropiprant was added to improve study adherence by reducing skin flushing, a common side-effect of niacin treatment. In HPS2-THRIVE, Lp(a) levels were only measured at 1 year in a randomly selected subset of 1,999 subjects and baseline levels are lacking. However results (50.7 vs 60.3 nmol/l at year 1, 17.8% difference) were comparable to AIM-HIGH. Both studies did not show a reduction in cardiovascular event rate, despite a potential beneficial effect on lipoprotein levels, including an average 20% reduction in Lp(a) levels. Of greater concern was the increased rate of serious adverse events in patients receiving niacin/laropiprant in HPS2-THRIVE, including increased occurrence of diabetic complications and incidence, serious infections, serious bleeding, gastro-intestinal complaints and myopathy. (26) In AIM-HIGH, without the addition of laropiprant, a similar profile of serious adverse event rates was observed, although not statistically significant, which is likely a reflection of the smaller study size. (27) by guest, on September 8, 2017 www.jlr.org
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Patients enrolled in HPS2-THRIVE and AIM-HIGH had very well controlled baseline lipid profiles and the main criticism on these studies is centered on the question of whether these patients should have been treated at all, as they already met the most stringent criteria for lipid control at baseline. (28) The same goes for Lp(a) levels in these studies, no current guidelines advise treatment of baseline levels of 36 nmol/l (AIM-HIGH) or 60 nmol/l (HPS2-THRIVE), (roughly equivalent to 15mg/dl and 25 mg/dl) (29) and it must be stressed that these studies were not specifically designed for patients with elevated Lp(a).
Apart from the average Lp(a) reduction of 20% by niacin, the inter-individual response is variable and more potent Lp(a) lowering by niacin has been reported in some cases. (30) Factors that determine Lp(a) response to niacin treatment have not been fully elucidated, for instance, apo(a) genotype status did not predict Lp(a) reduction and high Lp(a) levels at baseline were associated with increased response to niacin. (31, 32) One of the key questions is whether a selection of patients with high baseline Lp(a) levels did benefit from niacin treatment. A post-hoc analysis of AIM-HIGH (32) showed that 30% of the study population had baseline Lp(a) levels >100nmol/l. In addition, response to niacin was increased in the subgroups with higher Lp(a) levels: 20%, 39% and 64% Lp(a) decrease in 50 th , 75 th and 90 th percentile, respectively. There was no significant difference in event rate, however, between the niacin and placebo group for any quartile of baseline Lp(a), indicating the highest quartile of Lp(a) (median 125 nmol/l) did not benefit from the addition of niacin on top of statin background therapy. As Lp(a) levels in HPS2-THRIVE were only measured in a relatively small subset at year 1 and not at baseline, (26) it is unlikely that post-hoc analysis on high Lp(a) patients in HPS2-THRIVE will become available soon. Apart from the lessons learned from the impact of niacin on Lp(a), it should be realized that while it continues to be available in the US, niacin is no longer available in the European market, in view of the unfavorable harm versus health balance of this compound.
CETP inhibitors. (ACCELERATE) was terminated early for futility by the data safety monitoring board,(38) despite potent LDL-C lowering in phase 2 trials and thus presumably also an Lp(a) lowering effect. (37) Detailed study data from ACCELERATE will have to be awaited for a final verdict.
ApoB antisense and MTP inhibitors: targeting apoB production
Targeting apoB in the process of gene translation can block apoB-100 mRNA translation through the use of a single-strand antisense oligonucleotide (ASO) that is complementary to the mRNA.
Mipomersen, an ASO targeting apoB, was shown to reduce apoB lipoproteins and Lp(a) in a dosedependent manner by 38-48% and 26-27%, respectively (39, 40) whereas the results were slightly Currenlty, both apoB antisense and MTP inhibition therapy are only approved for lowering LDL-C levels in homozygous FH patients and, as noted, both of these agents have side effects. Therefore, these agents are unlikely to be approved for Lp(a) lowering in the near future.
PCSK9
Based on initial genetic studies, circulating proprotein convertase subtilisin kexin type 9 (PSCK9) was 
Lipoprotein apheresis
Currently available interventions targeting the apoB component of Lp(a) only effectuate a modest (10-40%) reduction in Lp(a) levels, which is expected to be insufficient to attenuate the pro-atherogenic potential of strongly elevated Lp(a) levels. A more effective Lp(a) lowering strategy is lipoprotein apheresis. Lipoprotein Apheresis (LA) removes apoB-containing lipoproteins, as well as the levels of associated oxidized phospholipids.(55) In a cohort study of 120 patients with elevated Lp(a) plasma levels (117.9±42.0 mg/dL) but otherwise well controlled risk factors, the mean annual major adverse coronary events (MACE) rate per patient was reduced significantly from 1.06 to 0.14 after LA (56) . In a recent prospective study performed in 170 patients (104.9±45.7 mg/dL) MACE also declined from 0.41 for 2 years before LA to 0.09 for 2 years during LA (57) . Whereas these small-scaled studies hint towards clinical benefit from lowering Lp(a) levels, the interpretation is hampered by the concomitant lowering of other atherogenic apoB containing particles including LDL-C up to 75%. Obviously, the invasive nature and high costs also preclude wider use of this technique in large numbers of patients.
Finally, one important caveat is the intermittent nature of the therapy. Lp(a) levels tend to rebound to 80% of baseline levels before the next apheresis session. (57) The resulting saw-tooth pattern in lipid levels is likely to decrease any beneficial impact of Lp(a) reduction . Thus, in vitro studies suggest a rapid detrimental effect, within minutes, of elevated Lp(a) (58) , indicating that the short rebound spikes in Lp(a) levels before apeheresis might pose a repetitive pro-atherogenic challenge, supporting the need for therapies that result in stable and potent Lp(a) reduction.
Non-apoB directed therapies
It is of interest that chronic inflammatory conditions such as rheumatoid arthritis and Crohn's disease are associated with elevated Lp(a) levels, indicating a key regulatory role for the innate immune Others have reviewed these compounds previously(64-67).
Future perspective: going from apoB to apo(a)
Given the crucial role of apo(a) genotype in determining the plasma concentration of Lp(a), targeting apo(a) may provide a more selective and attractive therapeutic target. Antisense oligonucleotide (ASOs) therapies directed at apo(a) synthesis hold a great promise as a future therapeutic strategy (68, 69) . Recently, data from a phase 1 study was published indicating Lp(a) lowering up to 78% could be reached.(70) Such agents with specific Lp(a) lowering efficacy will pave the way to establish the role of Lp(a) lowering in CVD prevention. These options will be discussed in a separate review article in this Thematic Series.
Concluding remarks
Whereas the Mendelian randomization approaches have firmly established the causality of Lp(a) in atherosclerosis and CVD-risk, the next challenge will be to prove that Lp(a) lowering also leads to 
